Head-to-head
bmiMD vs TMates
Compared on both medications across the eight dimensions this database records. They differ on 5 of those eight. bmiMD is cheaper on all-in tirzepatide at 10 mg/week, though on a flat-versus-tiered matchup the cheaper program can change further up the dose ladder.
The short answer
bmiMD is $179 a month all-in for tirzepatide; TMates is $297. Over twelve months that is $1,668 against $2,004. Value Scores are 91.6 and 55.3 out of 100.
Tirzepatide
Plan pages: bmiMD plans · TMates plans
At 10 mg/week, bmiMD is $179 a month all-in and TMates is $297 — $118 apart, or $1,416 across a year. Over twelve months the totals are $1,668 (prepaid term) and $2,004 (prepaid term).
bmiMD charges a flat $179 per month for tirzepatide at every dose from 2.5 to 15 mg per week, so titrating upward does not change what you pay.
TMates charges a flat $297 per month for tirzepatide at every dose from 2.5 to 15 mg per week, so titrating upward does not change what you pay. The company publishes no price at 5, 7.5, 12.5, 15 mg, so those doses are left blank rather than estimated.
| Dose | bmiMD | Rank | TMates | Rank | Cheaper |
|---|---|---|---|---|---|
| 2.5 mg | $179 | 5/31 | $297 | 16/31 | bmiMD by $118 |
| 5 mg | $179 | 3/17 | — | — | only bmiMD publishes |
| 7.5 mg | $179 | 3/17 | — | — | only bmiMD publishes |
| 10 mg | $179 | 3/27 | $297 | 12/27 | bmiMD by $118 |
| 12.5 mg | $179 | 3/17 | — | — | only bmiMD publishes |
| 15 mg | $179 | 3/17 | — | — | only bmiMD publishes |
bmiMD is cheaper at every dose where both publish a price, so the lead does not change as you titrate.
Across the 27 programs this database can rank on tirzepatide, bmiMD sits 2 of 27 on all-in monthly cost and TMates sits 10. There are 7 other programs priced between them. The field median is $339 and the floor is $169, so both sit below the median. bmiMD is $10 above the cheapest tirzepatide program on record. TMates is $128 above the cheapest tirzepatide program on record.
LillyDirect (Zepbound), the lowest FDA-approved tirzepatide channel here, is $449 a month — bmiMD undercuts it by $270, TMates by $152. Compounded products are not FDA approved; insurance can reverse that comparison.
| Plan term | bmiMD | TMates | Cheaper |
|---|---|---|---|
| Month to month | $179 | $297 | bmiMD by $118 |
| 3-month term | $159 | — | only bmiMD publishes this term |
| 6-month term | $149 | — | only bmiMD publishes this term |
| 12-month term | $139 | $167 | bmiMD by $28 |
| Settled dose | bmiMD | TMates | Difference |
|---|---|---|---|
| 2.5 mg | $2,148 | $3,564 | $1,416 apart |
| 5 mg | $2,148 | — | one side unpriced |
| 7.5 mg | $2,148 | — | one side unpriced |
| 10 mg | $2,148 | $3,564 | $1,416 apart |
| 12.5 mg | $2,148 | — | one side unpriced |
| 15 mg | $2,148 | — | one side unpriced |
TMates publishes none for 3-month term, 6-month term. An unpublished term is not necessarily unavailable — it is unpriced in public, which you can only resolve by asking.
A titration year is not twelve months at the maintenance price. Stepping up roughly four weeks per dose before settling at 10 mg/week, the first twelve months work out to $2,148 on bmiMD and $3,564 on TMates. The ramp is cheaper than the settled rate on whichever program prices by dose, which is why a first-year quote and a steady-state quote are not the same number.
That calculation is partial: TMates publishes no price at 2 of them, so the maintenance rate stands in for the missing steps rather than a number the company has stated.
Value Scores are 91.6 for bmiMD and 55.3 for TMates, against a tirzepatide category floor of $169. bmiMD leads by 36.3 points, driven mostly by price.
| Program | Price /70 | Evidence /15 | Dose /10 | Membership /5 | Total /100 |
|---|---|---|---|---|---|
| bmiMD | 66.1 | 10.5 | 10 | 5 | 91.6 |
| TMates | 39.8 | 10.5 | 0 | 5 | 55.3 |
Semaglutide
Plan pages: bmiMD plans · TMates plans
At 2.4 mg/week, bmiMD is $129 a month all-in and TMates is $249 — $120 apart, or $1,440 across a year. Over twelve months the totals are $1,188 (prepaid term) and $1,896 (prepaid term).
bmiMD charges a flat $129 per month for semaglutide at every dose from 0.25 to 2.4 mg per week, so titrating upward does not change what you pay.
TMates charges a flat $249 per month for semaglutide at every dose from 0.25 to 2.4 mg per week, so titrating upward does not change what you pay. The company publishes no price at 0.5, 1, 1.7 mg, so those doses are left blank rather than estimated.
bmiMD is cheaper at every dose where both publish a price, so the lead does not change as you titrate.
Value Scores are 95.5 for bmiMD and 51.8 for TMates, against a semaglutide category floor of $129. bmiMD leads by 43.7 points, driven mostly by price.
Where the two programs differ
All-in monthly
bmiMD is cheaper month to month — $179 against $297, a gap of $118 every month, or $1,416 across a year if both rates hold.
Cancellation terms
Cancellation differs: bmiMD states Per provider terms; confirm cancellation policy at enrollment, while TMates states Per provider terms. Read this next to the twelve-month figures — a prepaid discount and a restrictive refund policy are the same decision.
Commitment
bmiMD asks for Monthly, 3-month, 6-month, or 12-month plans; price varies by term, not by dose; TMates asks for 12-month plan or month-to-month; substantial difference in rates. This is the dimension most likely to change which program is actually cheaper for you, because the lowest rates on both sides are usually attached to the longest terms.
Dose policy
bmiMD charges one price at every dose; TMates prices by dose. That difference usually matters more than the headline gap, because the tiered program's advertised figure describes the dose you start on, not the dose you settle at.
Twelve-month cost
Over twelve months the totals are $1,668 for bmiMD and $2,004 for TMates. bmiMD is lower by $336 — a figure worth checking against the cancellation terms below, because a prepaid year is only cheaper if you stay on it.
Evidence status
Both figures carry the same evidence status, reported: sourced from dated third-party reporting; first-party capture pending. Neither is stronger than the other on provenance.
Membership fee
Neither charges a separate membership fee.
Shipping
Shipping is handled the same way by both — included in the quoted price.
What each record says
bmiMD Official site
bmiMD is a compounded GLP-1 telehealth platform notable for flat per-dose pricing — the rate stays the same whether you're at 2.5 mg or 15 mg — and one of the widest plan-tier menus in the market. Its $99/mo semaglutide and $139/mo tirzepatide on the twelve-month plan are the lowest annualized figures in the dataset for both molecules.
It does not publicly name its compounding pharmacy; the record shows Named 503A pharmacy partner (specific pharmacy not publicly identified on pricing page), so who actually makes the medication cannot be independently verified; commitment terms are Monthly, 3-month, 6-month, or 12-month plans; price varies by term, not by dose; cancellation is Per provider terms; confirm cancellation policy at enrollment; availability is stated as Availability at enrollment; confirm your state at intake.
Evidence: reported — sourced from dated third-party reporting; first-party capture pending, captured . Source — rangeyourself.com cheapest-compounded-tirzepatide-online, capture verified 2026-07-14
Watch: bmiMD's 12-month semaglutide plan at $99/mo is the lowest annualized sema figure in our dataset, beating NexLife's $119/mo and Oak's $133 m2m. Month-to-month sema at $129 also beats Oak's $133, making bmiMD the new m2m sema leader. Tirzepatide 12-month at $139 ties NexLife. Figures are reported status from RangeYourself's July 2026 first-party captures; our independent checkout is pending.
TMates Official site
TMates is a compounded GLP-1 telehealth service that includes medication and visits in one bundled monthly price. It offers both semaglutide and tirzepatide, with a 12-month plan that brings tirzepatide to $167/mo — the lowest committed-plan figure for tirz outside of bmiMD and NexLife.
It does not publicly name its compounding pharmacy; the record shows Partner 503A pharmacy (not publicly named), so who actually makes the medication cannot be independently verified; commitment terms are 12-month plan or month-to-month; substantial difference in rates; cancellation is Per provider terms; availability is stated as Confirm at intake.
Evidence: reported — sourced from dated third-party reporting; first-party capture pending, captured . Source — rangeyourself.com, capture 2026-07-14
Watch: The $158/mo (sema) and $167/mo (tirz) headline figures are 12-month plan rates; month-to-month is $249 (sema) and $297 (tirz) — some of the widest start-to-commitment spreads in the index. Reported status from RangeYourself 2026-07-14 verification.
What neither record tells you
bmiMD does not publish
- no named compounding pharmacy
- no state-by-state availability list — it says Availability at enrollment; confirm your state at intake
- no specific cancellation or refund terms
TMates does not publish
- no tirzepatide price at 5, 7.5, 12.5, 15 mg per week
- no semaglutide price at 0.5, 1, 1.7 mg per week
- no named compounding pharmacy
- no state-by-state availability list — it says Confirm at intake
- no specific cancellation or refund terms
Ask bmiMD and TMates for each of those in writing before enrolling. A gap is not evidence of a problem; it does mean nothing can be checked against it.
What would change this answer
Evidence may be upgraded. bmiMD, TMates carry a price we have not captured at checkout. A capture would move the evidence term and could reorder these two without any price changing.
Prepaid terms move the annual figures. bmiMD publishes a twelve-month rate of $139 a month against $179 month-to-month; TMates publishes a twelve-month rate of $167 a month against $297 month-to-month. Read those next to the cancellation terms, not the monthly rate.
Which one suits which reader
On the lowest standing monthly rate for tirzepatide, bmiMD Official site wins this matchup. If you expect to titrate to the top of the ladder, bmimd's flat pricing is worth more than the headline gap suggests.
Both figures should be checked at the provider's own checkout before you pay. bmiMD's tirzepatide price is reported as of 2026-07-14; TMates's is reported as of 2026-07-14.
Questions
Is bmiMD or TMates cheaper for tirzepatide?
bmiMD is cheaper on all-in monthly cost at 10 mg/week: $179 against $297, a difference of $118 a month. All-in means the medication plus every mandatory recurring fee.
What is the twelve-month cost of bmiMD versus TMates?
bmiMD works out to $1,668 across twelve months and TMates to $2,004, on the plan terms each publishes.
Does bmiMD or TMates raise the price as the dose goes up?
bmiMD: no, it charges one flat rate at every dose. TMates: yes, it prices by dose. Where one program is flat and the other is tiered, the cheaper of the two can change as you titrate upward.
How many ways do bmiMD and TMates differ?
5 of the eight dimensions this site records: all-in monthly, twelve-month cost, dose policy, membership, shipping, commitment, cancellation terms and evidence status.
Which of bmiMD and TMates names its pharmacy?
Neither. bmiMD records Named 503A pharmacy partner (specific pharmacy not publicly identified on pricing page) and TMates records Partner 503A pharmacy (not publicly named). Without a named pharmacy, neither program's licensing or inspection history can be checked before you order.
How well evidenced are the bmiMD and TMates prices?
bmiMD's tirzepatide figure is reported — sourced from dated third-party reporting; first-party capture pending — captured 2026-07-14. TMates's is reported, captured 2026-07-14. Evidence status is worth fifteen points in the Value Score, so it is priced in rather than mentioned as an aside.
Which is cheaper for semaglutide?
bmiMD, at $129 a month all-in against $249 at 2.4 mg/week. The two programs do not necessarily lead on both medications.
Official sources: bmiMD official site · TMates official site. Compounded tirzepatide and semaglutide are not FDA-approved products.